Baricitinib

29 trials 11 recruiting LOncology

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

11 Recruiting

13 Completed trials

18 Sponsors

22 Countries

Phase III

Phase II

Phase IV

Phase III: 11 Phase II/III: 2 Phase II: 8 Phase III/IV: 1 Phase IV: 7

Oversight events:

1 serious breach 1 temporary halt 1 unexpected event across 2 trials

View oversight register →

Indications tested

Polymyalgia rheumatica 2 Dermatomyositis 1 Rheumatoid arthritis 1 Juvenile idiopathic arthritis 1

Sponsors using this IMP

Eli Lilly & Co. 6 Assistance Publique Hopitaux De Paris 5 Centre Hospitalier Universitaire De Nantes 3 Aalborg University Hospital 1 Centre Hospitalier Regional Et Universitaire De Brest 1 Centre Hospitalier Universitaire De Bordeaux 1 Centre Hospitalier Universitaire Rouen 1 Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia 1 Hospital Universitario La Paz 1 IRCCS Istituto Giannina Gaslini 1 Les Hopitaux Universitaires De Strasbourg 1 Medical University Of Vienna 1

All trials — page 2

29 total

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricit… Ended

2024-518556-22-00 Phase III 3 countries Medical University Of Vienna
A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER) Ended

2024-516824-32-00 Phase III 2 countries Eli Lilly & Co.
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 Phase III 14 countries Oslo University Hospital Hf
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Ended

2023-507883-38-00 Phase III 7 countries Eli Lilly & Co.
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Phase IV 15 countries Eli Lilly & Co.

Showing 25–29 of 29 trials

← All drugs A–Z